Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568023 | 0.86 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2RXFP1GAA | |
| SCHEMBL2389846 | 0.86 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2RXFP1GAA | |
| SCHEMBL16181298 | 0.84 | ALDH1A1 (0.46) | MAPTALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL29935439 | 0.81 | ALDH1A1 (0.56) | MAPTALDH1A1SMN1; SMN2LMNARXFP1 | |
| SCHEMBL5653056 | 0.81 | GAA (0.54) | MAPTALDH1A1POLBKMT2AGAA | |
| SCHEMBL14367284 | 0.81 | GAA (0.54) | MAPTALDH1A1POLBKMT2AGAA | |
| SCHEMBL14367283 | 0.80 | SIRT6 (0.45) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL5652839 | 0.80 | SIRT6 (0.45) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL14711763 | 0.80 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2LMNARXFP1 | |
| SCHEMBL9969607 | 0.74 | MAPT (0.70) | MAPTALDH1A1SMN1; SMN2LMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | claimed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | claimed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | claimed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | claimed |
| US-9359285-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | disclosed |
| US-8865918-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | disclosed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | MAPT 4233/4885ALDH1A1 611/4885SMN1; SMN2 4789/4885 |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | MAPT 4233/4885ALDH1A1 611/4885SMN1; SMN2 4789/4885 |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | AR, SHBG, NR5A1 | MAPT 4233/4885ALDH1A1 611/4885SMN1; SMN2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.